Frontiers in Clinical Drug Research - Alzheimer Disorders

Volume 8

by

Atta-ur-Rahman

DOI: 10.2174/97898114018931190801
eISBN: 978-981-14-0189-3, 2019
ISBN: 978-981-14-0190-9
ISSN: 2451-8743 (Print)
ISSN: 2214-5168 (Online)



Indexed in: Scopus.

Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in dru...[view complete introduction]
US $
Buy Personal eBook
89
Order Library eBook
356
Order Printed Copy
*107
Order PDF + Printed Copy (Special Offer)
*151

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology

Could Antibiotics Be Therapeutic Agents in Alzheimer’s Disease?

- Pp. 81-128 (48)

Oscar Gomez-Torres, Cristina Pintado-Losa, Maria Rodriguez-Perez and Emma Burgos-Ramos

Abstract

Alzheimer´s disease (AD) is an irreversible neurodegenerative disorder and one of the main aging-dependent maladies of the 21st century. Around 46 million people suffer from AD worldwide and this is projected to double within the next 20 years. Due to the progressive aging of the population and the prediction of an increase in the incidence of this disease, AD constitutes a serious familial and social health problem. Therefore, it is necessary to find new therapeutic strategies which are aimed to prevent, delay the onset, slow the progression and/or improve the symptoms of AD. Currently, the research is focused on finding and identifying new drugs for achieving these goals.

In this chapter of the book, we widely review the neuroprotective role that some antibiotics could play in AD, because these drugs reach the brain quickly and are relatively inexpensive. Likewise, we have found evidence in both in vitro and in vivo studies and also in some clinical trials. In summary, all the reviewed antibiotics exert neuroprotection because they act on the main pathophysiological features of AD. Nevertheless, it must be taken into account that a long-term treatment with antibiotics could cause adverse effects including antibiotic resistance. Thus, properly clinical trials should be carried out in order to corroborate benefits of these antibiotics in people with AD.



Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science